Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib

A 30 year-old man with acute myeloblastic leukemia and secondary myelodysplastic syndrome developed graft-versus-host disease. The patient was treated with ruxolitinib. After being treated for 3 months with ruxolitinib, an inhibitor of Janus kinase, he developed Aspergillus retinal necrosis resistan...

Full description

Saved in:
Bibliographic Details
Published in:Archivos de la Sociedad Española de Oftalmología (English ed.) 2019-05, Vol.94 (5), p.237-241
Main Authors: Moruno-Rodríguez, A., Sánchez-Vicente, J.L., Rueda-Rueda, T., Lechón-Caballero, B., Muñoz-Morales, A., López-Herrero, F.
Format: Article
Language:English
Subjects:
Acute myeloblastic leukemia
Adult
Aspergillosis - complications
Aspergillosis - drug therapy
Aspergillus
Aspergillus flavus - isolation & purification
Aspergillus niger - isolation & purification
Enfermedad injerto contra huésped
Eye Infections, Fungal - microbiology
Fatal Outcome
Graft vs Host Disease - drug therapy
Graft-versus-host disease
Humans
Ischemia - diagnostic imaging
Leucemia mieloblástica aguda
Leukemia, Myeloid, Acute - drug therapy
Male
Myelodysplastic syndrome
Myelodysplastic Syndromes - etiology
Necrosis - microbiology
Necrosis retiniana
Opportunistic Infections - microbiology
Pyrazoles - adverse effects
Retina - pathology
Retinal necrosis
Retinal Vessels - diagnostic imaging
Ruxolitinib
Síndrome mielodisplásico
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 30 year-old man with acute myeloblastic leukemia and secondary myelodysplastic syndrome developed graft-versus-host disease. The patient was treated with ruxolitinib. After being treated for 3 months with ruxolitinib, an inhibitor of Janus kinase, he developed Aspergillus retinal necrosis resistant to common treatment. Treatment with Janus kinase inhibitors may lead to an increased incidence of opportunistic infections. Janus kinase inhibitor administration may result in poor treatment efficacy. Varón de 30 años de edad con leucemia mieloblástica aguda y síndrome mielodisplásico secundario que desarrolló una enfermedad injerto contra huésped. El paciente fue tratado con ruxolitinib, un inhibidor de la Janus quinasa. A los 3 meses de haber iniciado el tratamiento se produjo una necrosis retiniana por Aspergillus, sin respuesta al tratamiento. El tratamiento con inhibidores de la Janus quinasa favorecería un aumento en la incidencia de infecciones oportunistas. El uso de estos fármacos podría dar lugar a una menor eficacia de los tratamientos empleados.
ISSN:2173-5794
2173-5794
DOI:10.1016/j.oftale.2018.12.009